en · de · es · fr · pt
semax-notes.peptides6908.com › Guide › Semax �š„分子背景与结构 — Field Notes

Semax �š„分子背景与结构 — Field Notes

By Editorial Desk · published 2025-11-10 · last reviewed 2025-12-17 · Guide

ACTH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-12-17. Where a claim depends on a specific study, the study is described rather than over-claimed.

Semax 的分子背景与结构

该化合物于二十世纪八十年代在俄罗斯被开发,相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性,而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示,这一方向促成了多个相关短肽的合成与筛选,而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。

研究兴趣主要集中在神经营养因子相关的路径上,包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升,但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验,人体对照研究数量有限。因此,该化合物的作用机制在文献中属于活跃讨论,而非已经确立的定论。

Semax 是一种人工合成的七肽,氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro,单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物,但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly,Semax 替换了中间两个残基,并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。

Mechanism and Research Context

The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.

Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.

Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.

Semax at a glance

PropertyValueNotes
化学类别合成七肽ACTH(4-10) 结构类似物
氨基酸序列Met-Glu-His-Phe-Pro-Gly-Pro单字母写作 MEHFPGP
分子量约 813.9 Da随确切形式和盐型略有变化
常见同义词ACTH(4-10) 类似物俄语文献称 Семакс
开发来源俄罗斯二十世纪八十年代

Semax Origin and Molecular Structure

The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.

Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.

Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.

Related pages on this site

Storage Handling and Analytical Verification

Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.

Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.

Background and Development

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Supporting material

Before the infusions, participants received oral corticosteroids, histamine receptor blockers, and acetaminophen to reduce the risk of infusion-related reactions, which by themselves will cause several side effects.

20–30, 1991 Salgues, E., "Naram-Sin's conquests of Subartu and Armanum", Akkade is King. A collection of papers by friends and colleagues presented to Aage Westenholz on the occasion of his 70th birthday 15 May 2009, hrsg. v. Gojko Barjamovic (Uitgaven van het Nederlands Instituut voor het Nabije Oosten te Leiden 118), pp. 253–272, 2011 Steinkeller, Piotr, "The Roundlet of Naram-Suen", History, Texts and Art in Early Babylonia: Three Essays, Berlin, Boston: De Gruyter, pp. 158–164, 2017 F.Thureau-Dangin, Une inscription de Naram-Sin", Revue d’Assyriologie et d’archéologie Orientale, vol. 8, no. 4, pp. 199–200, 1911

== References == This article was adapted from the following source under a CC BY 4.0 license (2019) (reviewer reports): Stephen Branden Van Oss; Anne-Ruxandra Carvunis (2019). "De novo gene birth". PLOS Genetics. 15 (5) e1008160. doi:10.1371/journal.pgen.1008160. PMC 6542195. PMID 31120894. Wikidata Q86320144.

Sources: en.wikipedia.org

Supporting material

== Awards and recognition == Fellow, American Association for the Advancement of Science (1995) Fellow, Academy of Toxicological Sciences (2000) Public Communications Award, Society of Toxicology (2014) Excellence in Pharmacology/Toxicology Lifetime Award, PhRMA Foundation (2015) David Rall Medal, National Academy of Medicine (2020) Merit Award, Society of Toxicology (2024)

=== Split flow thin-cell fractionation === Split flow thin-cell fractionation (SPLITT) is a special preparative FFF technique, using gravity or electric, or diffusion differences for separation of over μm-sized particles on a continuous basis. SPLITT system has two inlets and two outlets. It is performed by pumping the sample immerse in a liquid into one inlet at the start of the channel at low flow-rate, whilst simultaneously pumping a carrier liquid into the second inlet at much higher flow-rate. By controlling the flow rate ratios of the two inlet streams and two outlet streams, the separation can be controlled, and the sample components are separated into two distinct sized fractions. The use of gravity alone as the separating force makes SPLITT the least sensitive FFF technique, limited to particles above 1 μm.

Under the influence of estrogen, stromal and fat tissue surrounding the ductal system in the mammary glands also grows. After puberty, GH and IGF-1 levels progressively decrease, which limits further development until pregnancy, if it occurs. During pregnancy, progesterone and prolactin are essential for mediating lobuloalveolar development in estrogen-primed mammary gland tissue, which occurs in preparation of lactation and nursing. Androgens such as testosterone inhibit estrogen-mediated mammary gland development (e.g., by reducing local ER expression) through activation of androgen receptors expressed in mammary gland tissue, and in conjunction with relatively low estrogen levels, are the cause of the lack of developed mammary glands in males.

Sources: en.wikipedia.org

Supporting material

Curettage ( or ), in medical procedures, is the use of a curette (French, meaning "scoop") to remove tissue by scraping or scooping. Curettages are also a method of abortion. It has been replaced by vacuum aspiration over the last decade. Curettage has been used to treat teeth affected by periodontitis.

Sarcosine, also known as N-methylglycine, or monomethylglycine, is a non-proteinogenic amino acid with the formula CH3N(H)CH2CO2H. It is the N-methyl derivative of glycine, with a secondary amine in place of the primary amine, and occurs naturally in muscles and other body tissues as an intermediate in the metabolism of choline to glycine. It was first isolated and named by the German chemist Justus von Liebig in 1847. Sarcosine is ubiquitous in biological materials. It is used in manufacturing biodegradable surfactants and toothpastes as well as in other applications. It is also a reagent in organic synthesis. It has a mildly sweet taste. Pharmacologically, sarcosine functions as a competitive inhibitor of the glycine transporter type 1 (GlyT1), a co-agonist at the glycine binding site of the NMDA receptor, and, at higher concentrations, an agonist at the strychnine-sensitive glycine receptor. These properties have led to its investigation as an adjunctive treatment in schizophrenia and major depressive disorder. Sarcosine has also been identified as an oncometabolite in prostate cancer, where elevated levels correlate with disease progression and metastatic potential.

=== First steps, under Field === Field's failure to secure independence concurrently with the end of the Federation caused his Cabinet's support for him to waver during late 1963 and early 1964. The RF caucus in January 1964 revealed widespread dissatisfaction with him on the grounds that the British seemed to be outwitting him. The Prime Minister was put under immense pressure to win the colony's independence. Field travelled to England later that month to press Douglas-Home and Sandys for independence, and raised the possibility of UDI on a few occasions, but returned empty-handed on 2 February. The RF united behind Field after Sandys wrote him a terse letter warning him of the likely Commonwealth reaction to a declaration of independence, but the Prime Minister then lost his party's confidence by failing to pursue a possible route to at least de facto independence devised by Desmond Lardner-Burke, a lawyer and RF MP for Gwelo. During March 1964, the Legislative Assembly in Salisbury considered and passed Lardner-Burke's motion that the Governor, Sir Humphrey Gibbs, should submit a petition to the Queen requesting alteration of Section 111 of the 1961 constitution so that the Royal Assent described therein would be exercised at the request of the Southern Rhodesian government rather than that of its British counterpart. This would both remove the possibility of British legislative interference and pave the way for an attempted assumption of independence by Order in Council.

Extrapyramidal signs Rhabdomyolysis, acute Ataxia Irregular heart beat Mild hypothyroidism Loss of milestones Delayed speech and language acquisition Delayed walking Abnormal liver enzymes Gastrointestinal dysmotility Generalised brain atrophy High blood ammonia levels Low blood sugar Involuntary muscle contractions Increased lactate in body Prolonged QT interval Seizure Occasional:

Sources: en.wikipedia.org

Frequently asked questions

Semax 是天然存在的物质吗?

不是。Semax 是完全人工合成的七肽,自然界中没有对应的已知肽段。它的设计灵感来自促肾上腺皮质激素片段 ACTH(4-10),但序列经过了替换和延长。

Semax 与 ACTH 是什么关系?

Semax 被描述为 ACTH(4-10) 的结构类似物,两者共享部分序列特征。它保留了该片段的部分神经相关活性方向,但去除了完整片段带来的激素释放效应。二者并非同一物质,也不能互相替代。

为什么 Semax 的序列需要在羧基端延长?

加入的 Pro-Gly-Pro 三肽被普遍认为能提升分子对蛋白水解酶的稳定性。这种设计让短肽在体内维持时间更长。具体延长的程度以及不同组织中是否一致,文献中仍存在不同报告。

What does the evidence base look like?

It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.

Network